To assess the clinical relevance of these findings, the in vivo effects of metformin on CD34+ leukemia stem/progenitor cells were further evaluated by patient-derived xenograft (PDX) CML models. Here, CD34 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.